GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come
August 26, 2009
GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come
Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter - FDA Updates Plavix Label with PGx Data, but Does Not Provide Dosing Recommendations
June 17, 2009 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter